Beam Therapeutics Inc. ( NASDAQ:BEAM – Get Rating ) – Jefferies Financial Group upped their FY2023 earnings per share estimates for shares of Beam Therapeutics in a report released on Tuesday, February 28th. Jefferies Financial Group analyst M. Yee now expects that the company will post earnings per share of ($6.12) for the year, up from their previous estimate of ($6.22). The consensus estimate for Beam Therapeutics' current full-year earnings is ($5.54) per share. Jefferies Financial Group also issued estimates for Beam Therapeutics' Q4 2023 earnings at ($1.

https://www.dailypolitical.com/2023/03/03/jefferies-financial-group-weighs-in-on-beam-therapeutics-inc-s-fy2023-earnings-nasdaqbeam.html

#dailypolitical